Wilson Troy Edward insider trades
Wilson Troy Edward has filed 33 Form 4s with the SEC that we hold, for Kura Oncology, Inc. (KURA) (President and CEO, Director), Puma Biotechnology, INC. (PBYI) (Director), RNAM (Director) and Atrium Therapeutics, Inc. (RNA) (Director). Across all of them we count 5 purchases worth $3.1M and 15 sales worth $6.9M reported on Form 4. In the last 12 months: 2 purchases ($2.4M) and 2 sales ($123.3K). The largest single trade was a sale of 84,107 shares of Kura Oncology, Inc. worth $1.7M, dated 2024-01-24. Of 1 sale filed since we began reading the 10b5-1 checkbox, 1 (100%) was marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2022-01-28 and the latest 2026-09-16.
Kura Oncology, Inc. (KURA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-01-24 | S, sale reported on Form 4 | 6,945 | $140.5K | 2024-01-26 |
| 2024-01-24 | S, sale reported on Form 4 | 84,107 | $1.7M | 2024-01-26 |
| 2025-08-12 | P, purchase reported on Form 4 | 36,506 | $213.6K | 2025-08-14 |
| 2025-08-13 | P, purchase reported on Form 4 | 13,494 | $89.6K | 2025-08-14 |
| 2025-09-08 | P, purchase reported on Form 4 | 50,000 | $410.0K | 2025-09-09 |
| 2025-09-29 | S, sale reported on Form 4 | 36,615 | $327.3K | 2025-09-29 |
| 2026-08-17 | P, purchase reported on Form 4 | 100,000 | $1.1M | 2026-08-17 |
| 2026-08-24 | P, purchase reported on Form 4 | 100,000 | $1.2M | 2026-08-24 |
Puma Biotechnology, INC. (PBYI)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-06-16 | S, sale reported on Form 4 | 27,858 | $71.9K | 2022-06-21 |
| 2023-06-13 | S, sale reported on Form 4 | 27,000 | $93.2K | 2023-06-15 |
| 2024-06-13 | S, sale reported on Form 4 | 27,000 | $89.9K | 2024-06-17 |
| 2025-06-13 | S, sale reported on Form 4 | 10,800 | $36.7K | 2025-06-17 |
| 2026-06-12 | S, sale reported on Form 4 | 10,800 | $77.8K | 2026-06-15 |
| 2026-09-14 | S, sale reported on Form 4 | 5,000 | $45.5K | 2026-09-16 |
RNAM
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2025-08-06 | S, sale reported on Form 4 | 15,000 | $675.0K | 2025-08-08 |
| 2025-08-06 | S, sale reported on Form 4 | 7,500 | $337.5K | 2025-08-08 |
| 2025-08-06 | S, sale reported on Form 4 | 22,000 | $990.0K | 2025-08-08 |
| 2025-08-06 | S, sale reported on Form 4 | 17,777 | $800.0K | 2025-08-08 |
| 2025-09-05 | S, sale reported on Form 4 | 15,000 | $750.0K | 2025-09-09 |
| 2025-09-05 | S, sale reported on Form 4 | 14,500 | $725.0K | 2025-09-09 |
Atrium Therapeutics, Inc. (RNA)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1589597) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms